Data highlight potential for new diagnostics and therapeutics targeting red meat allergy SOUTH SAN FRANCISCO, Calif., Feb. 10 ...

It is closely associated with tumorigenesis and drug resistance, making it a potential target for oncology drug development. To date, no ROR1-targeting drugs have been marketed. BR111 utilizes ...

In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve ...

Mozart Therapeutics, the leading developer of CD8 Treg network modulators in autoimmune disease, announces the presentation ...

Cambridge, Massachusetts Thursday, February 6, 2025, 13:00 Hrs [IST] ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the 'Company'), a global ...

Humoral immunity refers to antibody-mediated immune responses. Antibodies are produced by plasma cells and protect the host from infection in three main ways: by binding to pathogens to inhibit ...

Induces potent and long-lasting immune responses to defined antigens or whole pathogens (particles), mainly through the induction of high-affinity antibodies derived from GCs and produced by ...

A breakthrough discovery in enzyme science could revolutionize the treatment of autoimmune disorders and other diseases tied to the overactivity of antibodies. Published in the journal, ...

Explore the structure of the antibody and the four main ways antibodies function when binding to pathogens with the image below. The cell-mediated response is the other path of the adaptive immune ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...